Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JT-003 Add-on in Type 2 Diabetes Inadequately Controlled with Metformin and Dapagliflozin
NCT05296044Phase 3Unknown
- Sponsor
- Jeil Pharmaceutical Co., Ltd.
- Start
- Apr 2022
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of pioglitazone in type 2 diabetes mellitus (T2DM), sponsored by Jeil Pharmaceutical Co., Ltd.. Status: unknown.
02
Drugs
pioglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05296044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05296044.